The Need for Better Minority Enrollment in Multiple Myeloma Clinical Trials

Multiple myeloma is more deadly for Black people, who are not adequately represented in clinical trials. There are reasons for this, including lack of information, distrust of the medical system, financial barriers, and strict inclusion criteria. The FDA has issued new guidance to increase minority participation in trials, including broadening eligibility criteria, appointing diversity officers, and tapping into community-based centers. Initiatives like the CureCloud study aim to address these barriers. Research also shows genetic differences in multiple myeloma among African Americans. Addressing these issues is crucial to understanding the efficacy of treatments for all patients.

Source link

error: Content is protected !!